A Novel Pharmacological Therapy for Obstructive Sleep Apnea
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains
elusive. Here the investigators study the effect on sleep apnea severity of a combination of
pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time.
The current study will answer the following questions: Does ongoing, repeated-dose
administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity,
and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic
subgroup of patients preferentially benefit from this intervention?